GIP Decreases Valine Consumption in the VAT of Non-Obese Controls, and It Increases Valine and Pyroglutamate Consumption in the VAT of Patients with Obesity and Obesity with Concomitant Prediabetes, Respectively. This evidence concerns the gene GIP and obesity disorder.